CytaCoat

Medical Coating Solution

CytaCoat develops a permanently bonded, non-leaching superhydrophilic surface coating that reduces biofilm formation by modulating microbial behavior rather than relying on biocidal release. The initial commercial focus is on wound care dressings and catheter coatings.

Founded 2001
SMA Investment 2020
CEO Graeme Brookes
Chairman Wolfgang Reim
Head Offices Stockholm
SMA Board Representation Karin Leire (board member)